Full-Time

Associate Director

Patient Access and Reimbursement

Updated on 9/4/2026

Mirum Pharmaceuticals

Mirum Pharmaceuticals

201-500 employees

ASBT inhibitors for rare liver diseases

No salary listed

Remote in USA

Remote

Candidate should live in the Midwest; travel up to 50% of the time is required.

Bachelor's

Category
Customer Experience & Support (1)
Required Skills
CRM
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Mirum Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in business, science, or a related field is required.
  • At least 8 years of pharmaceutical or biotechnology experience is required.
  • At least 4 years of experience with specialty products in the orphan or rare disease space is required.
  • Strong understanding of the payer landscape, payer accounts, and market access experience is required.
  • Ability to travel up to 50% of the time is required.
  • Ability to anticipate and resolve problems effectively.
  • High demonstrable proficiency in Excel and PowerPoint.
  • Ability to organize and prioritize various activities.
  • Demonstrated flexibility when working with people, processes, and systems in a complex environment.
  • Ability to multitask and remain responsive to internal and external customers while traveling.
  • Ability to influence without authority and collaborate cross-functionally.
  • Commitment to contributing to overall organizational success.
Responsibilities
  • Partner with Mirum stakeholders on account and territory strategy to increase internal and external customer knowledge of payer policy and Mirum Access Plus processes.
  • Act as a subject matter expert on the reimbursement and access landscape for Mirum therapies for cholestatic liver disease, including payer policies, prior authorization requirements, denials, appeals, and peer-to-peer processes.
  • Analyze and share insights on the reimbursement and access experience for Mirum therapies.
  • Provide targeted education to healthcare provider office staff on Mirum Access Plus and the access process.
  • Provide regional account managers and healthcare provider offices with patient-specific payer-policy education to support prior authorizations and appeals for enrolled, on-label patients.
  • Collaborate with the Mirum Access Plus supervisor and healthcare provider accounts on individual case-management needs related to reimbursement education.
  • Offer operational solutions and identify opportunities to improve healthcare provider access experiences by troubleshooting account access issues and collecting account feedback.
  • Conduct access-related business reviews with higher-volume healthcare provider accounts covering account-specific and national trends.
  • Attend weekly regional team meetings and keep regional teams informed of access trends involving patient enrollment forms and reimbursement access support activities with key accounts.
  • Support the continuing improvement and education of Mirum Access Plus Patient Navigators through call-calibration feedback and training to address knowledge gaps.
  • Develop compliant, customer-centric reimbursement educational materials.
  • Use data in individual cases to ensure accurate information flow.
  • Comply with laws, regulations, and policies governing Mirum activities.
  • Perform other assigned duties and projects.
Desired Qualifications
  • Three years of experience in field reimbursement, patient access and support, payer account management, or market access strategy and operations within the pharmaceutical or biotechnology industry is strongly preferred.
Mirum Pharmaceuticals

Mirum Pharmaceuticals

View

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2018

Get referred to Mirum Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 net product sales reached $176.2 million, and guidance rose to $700 million.
  • Rob Myers starts September 21, 2026, strengthening hepatology leadership before key readouts.
  • Volixibat, brelovitug, and zilurgisertib create multiple catalysts through first-half 2027.

What critics are saying

  • FDA recommended another volixibat Phase 3 on August 5, 2026, delaying PSC filing.
  • If LIVMARLI growth slows, Mirum loses the cash engine funding its pipeline.
  • Zilurgisertib’s September 26, 2026 PDUFA denial would crush sentiment and financing flexibility.

What makes Mirum Pharmaceuticals unique

  • LIVMARLI dominates rare pediatric cholestatic disease with expanding PFIC and biliary atresia labels.
  • Mirum combines commercialization strength with late-stage hepatology pipeline breadth across PSC, HDV, and FOP.
  • Exclusive zilurgisertib rights from Incyte add a near-term rare-disease launch platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Sep 8th, 2026
Mirum Pharmaceuticals appoints Dr Rob Myers as chief medical officer

Mirum Pharmaceuticals has appointed Dr Rob Myers as chief medical officer, effective 21 September 2026. Dr Myers will lead the company's global medical and clinical development functions. Dr Myers brings over 20 years of experience in drug development, with particular expertise in hepatology. He joins from OrsoBio, where he served as chief medical officer and head of development. Previously, he held senior leadership positions at Gilead Sciences, overseeing clinical development programmes across liver fibrosis, cholestatic liver diseases, and gastrointestinal inflammation. Dr Myers has published more than 200 peer-reviewed papers and has contributed to advancing understanding of primary sclerosing cholangitis. He holds an MD from Western University and a master's degree in epidemiology from the University of Calgary.

CNBC TV18
Aug 20th, 2026
US FDA approves Regeneron's rare bone disorder drug.

US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.

Yahoo Finance
Aug 6th, 2026
FDA requests Phase 3 trial for Mirum's Volixibat, delaying NDA until H1 2027 — MIRM stock crashes 15%

Mirum Pharmaceuticals shares plunged 15% on Thursday after the FDA recommended an additional Phase 3 study for its liver disease candidate Volixibat, potentially delaying the new drug application until the first half of 2027. Citizens lowered its price target to $137 from $146 whilst maintaining an Outperform rating. The regulatory setback overshadowed strong second-quarter results. Mirum reported revenue of $176.2 million, beating analysts' estimates of $167.3 million. The company raised its full-year net product sales guidance to $680 million to $700 million, from $660 million to $680 million. Mirum ended the quarter with $561.3 million in cash and equivalents. Volixibat has already received FDA Breakthrough Therapy and Orphan Drug designations.

Yahoo Finance
Aug 6th, 2026
Mirum raises 2026 guidance to $700M, delays PSC drug filing amid FDA review

Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $680 million to $700 million, citing growth in Alagille syndrome and expanding adult PFIC diagnosis. The company secured $690 million through a convertible note offering, improving its capital structure whilst settling 75% of 2029 notes. The firm identified a significant opportunity in adult PFIC, estimating at least 2,000 addressable patients each in the US and Europe. Commercial operations achieved a high-50s percent cash contribution margin, representing a 5 percentage point year-over-year improvement. Mirum delayed its volixibat PSC NDA submission due to alignment issues with FDA reviewers but received Breakthrough Therapy Designation. The company targets a first-half 2027 NDA submission for PSC and anticipates Phase III PBC results in Q1 2027.

Yahoo Finance
Aug 6th, 2026
Mirum Pharmaceuticals' Q2 revenue hits $176M, up 38% year-on-year despite widened loss

Mirum Pharmaceuticals reported revenue of $176.24 million for the quarter ended June 2026, up 37.9% year-over-year. The figure exceeded the consensus estimate of $164.76 million by 6.97%. The company posted a loss of $0.80 per share, compared to $0.12 a year ago, slightly missing the estimated loss of $0.77 per share. Product sales showed strong performance across categories. Livmarli generated $128.72 million, surpassing the $119.6 million analyst estimate. Bile acid medicines brought in $47.52 million, also beating expectations of $45.64 million. Despite beating revenue estimates, Mirum's shares fell 18.7% over the past month, underperforming the S&P 500's 3.5% gain.